Natural Capsules profitability ratios

Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025
Returns
−7.5%−7.5%0.3%
−5.9%−5.9%0.2%
−6.1%−6.1%2.6%
−4.6%−4.7%0.9%
Margins
−0.4%−0.8%10.4%
−10.0%−10.0%5.0%
—−150.6%—
−14.5%−14.9%1.6%
−13.0%−13.2%0.4%
—−9.1%—
−0.3%−0.3%−10.6%
Additional
10.3%11.7%77.9%
−7.5%−7.5%0.3%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

NATCAPSUQ₹136.44

Natural Capsules Limited

· Pharma & Health
₹ CrorePeersNECLIFEAAREYDRUGSBALPHARMAALPAKREBSBIOMEDICAMEQMEDICOVINEETLABMcap ₹142 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Returns
Return on Common Equity0.27-7.51-7.51
Return on Assets0.15-5.85-5.85
Return on Capital Employed2.63-6.12-6.12
Return on Invested Capital0.93-4.74-4.63
Margins
EBITDA Margin10.35-0.83-0.40
Operating Margin4.96-9.99-9.99
Incremental Operating Margin—-150.58—
Pretax Margin1.65-14.91-14.52
Net Income Margin0.36-13.17-13.02
Net Income to Common Margin—-9.12—
FCF Margin-10.57-0.33-0.33
Additional
Effective Tax Rate77.8811.6610.34
Sustainable Growth Rate0.27-7.51-7.51
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.